This Hated Stock Suddenly Looks Like a Bargain
- Dr. Bruce Moynihan
- Sep 23, 2025
- 5 min read
In the fast-moving world of pharmaceuticals, few stories have been as dramatic as the rise of weight-loss drugs. From GLP-1 therapies like Ozempic and Wegovy to a pipeline of next-generation treatments, the obesity drug market has quickly become one of the hottest growth stories in global healthcare. Investors are piling into companies with promising candidates, driving valuations into the stratosphere. Yet in the middle of this frenzy, one company that Wall Street had all but written off may now be positioning itself as the surprising budget entry point to the obesity bonanza: Pfizer. For years, Pfizer has been saddled with a reputation for underperformance, especially as its COVID-19 vaccine windfall evaporated and growth stalled. The stock has been widely described as “hated” by analysts, plagued by disappointing earnings reports and concerns over its pipeline. But with its latest deal in the obesity space, Pfizer may be giving investors a rare opportunity to buy into one of the most lucrative healthcare markets of the decade at a discount.
Want to read more?
Subscribe to doctorsinbusinessjournal.com to keep reading this exclusive post.
